The Anti-Aging Industry Is Calling Itself Precision Medicine. The Science Says Otherwise.
Every few months, a paper lands in a longevity journal and the anti-aging industry finds a new way to describe the same basic idea: zombie cells are bad, and killing them is good. The latest version comes from researchers at West China Hospital, Sichuan University, who published a sweeping review in Aging-US in early May arguing that the field needs to grow up. The real goal, they write, is not to eliminate all senescent cells but to target only the harmful ones while leaving the beneficial ones intact. Call it precision geroprotection. The press release wrote itself. The coverage followed.
Here is what the coverage left out: the authors admit, in the same paper, that nobody has figured out how to tell the difference.
Senescent cells are cells that have permanently stopped dividing. The traditional view holds that they accumulate with age, pump out inflammatory signals, and drive everything from arthritis to Alzheimer. The therapeutic logic is intuitive: find the cells, kill them. Dasatinib, quercetin, fisetin Aging-US review — the first-generation senolytics — do exactly that. They disrupt survival pathways and force senescent cells into programmed death. The problem is that they cannot distinguish a senescent hepatocyte helping to repair a liver wound from one driving chronic inflammation in the same organ. They are blunt instruments dressed up in the language of precision medicine.
The Deng and Yang review, published May 4 in Volume 18 of Aging-US Aging-US review, lays out the taxonomy in detail. It describes senescent cell subtypes across the liver, lungs, kidneys, heart, brain, skin, and fat tissue. It catalogues the difference between senescent cells that appear to limit fibrosis and assist tissue repair and those that appear to fuel chronic inflammation and cancer progression. And then, in the same document, it acknowledges the fundamental gap: there are no highly specific biomarkers that can reliably distinguish the harmful variants from the protective ones. The precision exists in the literature. The targeting does not.
This is not a minor technical footnote. It is the entire problem.
The heterogeneity of senescent cells is not a new discovery. A separate paper published in Aging-US last August by researchers at the Buck Institute for Research on Aging and Johns Hopkins Aging-US heterogeneity paper went further, showing that senescent cell subpopulations respond differently to senolytic treatment depending on their cell cycle status when they entered senescence. The implication cuts both ways: not only do broad senolytics kill beneficial cells alongside harmful ones, but they may not even kill all the harmful cells uniformly. Selectivity is more complicated than the drug design — it is written into the biology of each cell type.
The clinical trial record bears this out. A trial registered with the NIH ClinicalTrials.gov NCT04313634 tests whether senolytic drugs can reduce senescent cell burden and improve bone health in older women. The primary endpoints measure changes in bone formation and resorption markers — downstream outcomes, not biomarkers of cell-type specificity. Another trial tests fisetin in osteoarthritis ClinicalTrials.gov NCT04210986, measuring pain and joint function. None of these trials can claim they are hitting the right senescent cells. They are hitting senescent cells and hoping the net effect is beneficial.
Unity Biotechnology is the most clinically advanced senolytic company in the space, and its UBX1325 program is instructive. The compound — a BCL-xL inhibitor — showed results in a Phase 2 trial for diabetic macular edema published in NEJM Fight Aging! Unity coverage. Administered via injection into the eye, it demonstrated visual acuity gains non-inferior to anti-VEGF therapy at most timepoints. Unity describes UBX1325 as designed to eliminate senescent cells in diabetic retinal blood vessels while leaving healthy ones intact. That sounds like precision targeting. But the mechanism is not cell-type specificity — it is local delivery. The drug kills senescent cells wherever it is injected, not because it recognizes harmful subtypes, but because the eye is a contained compartment. Transplant that drug to the liver or the lung and the same selectivity argument collapses.
The market has absorbed this nuance selectively. The senolytic drugs market was valued at $2.8 billion in 2025 and is projected to reach $9.6 billion by 2034 Dataintelo market report, according to industry estimates. The investment narrative is consistently built around precision: the next generation of therapies, the biomarker-driven approach, the transition from blunt-force demolition to surgical targeting. The current generation — the pills and injections that make up the $2.8 billion — runs on the old logic. Dasatinib and quercetin are a decades-old cancer drug and a flavonoid found in many foods. Fisetin is a supplement. The precision framing is a destination the industry is describing, not a place it has arrived.
The authors of the Deng and Yang review propose a research agenda: single-cell omics, lineage tracing, spatial profiling Aging-US review — technologies that can begin to resolve the subtypes. They are right that these tools are advancing. They are also right that validated biomarkers for specific senescent cell populations in specific tissue types, usable as therapeutic targets, do not yet exist. The review does not offer a timeline for closing that gap. The companies raising money on precision senolytics do not either.
None of this means the current drugs are worthless. Dasatinib and quercetin have shown biological signals in human trials — changes in senescent cell burden, improvements in some health markers ClinicalTrials.gov NCT04313634. Unity Biotech is running a real Phase 2 program that produced real data Fight Aging! Unity coverage. The biology of senescence is real and the therapeutic interest is justified. What the science does not support is the framing that the field has moved beyond its crude first chapter into a precision era. That transition requires solving a problem the authors themselves identify as unsolved.
The anti-aging industry has built an impressive capacity for narrative. Zombie cells, senolytics, precision geroprotection — the terminology is evocative and the biological logic is intuitive enough to travel well beyond academic conferences. But the gap between the marketing and the underlying biology is wide enough to park a decade of research in. The next time a press release arrives with the phrase precision anti-aging, it is worth asking which biomarker makes it precise, and the honest answer is: none have been validated yet.